The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Maintenance Olaparib for Germline BRCA -Mutated Metastatic Pancreatic Cancer
Open accessAbstract
BACKGROUND: mutation make up a small subgroup of those with metastatic pancreatic cancer. The poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor olaparib has had antitumor activity in this population. METHODS: mutation and metastatic pancreatic cancer and disease that had not progressed during first-line platinum-based chemotherapy. Patients were randomly assigned, in a 3:2 ratio, to receive maintenance olaparib tablets (300 mg twice daily) or placebo. The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 3315 patients who underwent screening, 154 underwent randomization and were assigned to a trial intervention (92 to receive olaparib and 62 to receive placebo). The median progression-free survival was significantly longer in the olaparib group than in the placebo group (7.4 months vs. 3.8 months; hazard ratio for disease progression or death, 0.53; 95% confidence interval [CI], 0.35 to 0.82; P = 0.004). An interim analysis of overall survival, at a data maturity of 46%, showed no difference between the olaparib and placebo groups (median, 18.9 months vs. 18.1 months; hazard ratio for death, 0.91; 95% CI, 0.56 to 1.46; P = 0.68). There was no significant between-group difference in health-related quality of life, as indicated by the overall change from baseline in the global quality-of-life score (on a 100-point scale, with higher scores indicating better quality of life) based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (between-group difference, -2.47 points; 95% CI, -7.27 to 2.33). The incidence of grade 3 or higher adverse events was 40% in the olaparib group and 23% in the placebo group (between-group difference, 16 percentage points; 95% CI, -0.02 to 31); 5% and 2% of the patients, respectively, discontinued the trial intervention because of an adverse event. CONCLUSIONS: mutation and metastatic pancreatic cancer, progression-free survival was longer with maintenance olaparib than with placebo. (Funded by AstraZeneca and others; POLO ClinicalTrials.gov number, NCT02184195.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“HRD targeted therapy with PARPi is mostly restricted to breast and ovarian cancer5, though its use for treating pancreatic cancer was recently approved by the FDA (US Food and Drug Administration)29.”
From Pan-cancer landscape of homologous recombination deficiency. (2020) · cites this paper as [29]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredIn the citing paper
“Finally, in late-stage PDAC with germline mutation in BRCA1 or BRCA2 (~7.5% of the patients), the PARP inhibitor olaparib could extend progression free survival but not overall survival (8).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [8]
In the citing paper
“a pivotal clinical trial in patients with PDAC and germline BRCA1/2 mutations established the benefit of administering an orally bioavailable PARP inhibitor on improved progression free survival (PFS). This led to the approval of targeted therapy in this setting87.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
Self-citationOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642
Self-citationEpidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–400 of 1,002
Fumet, J.-D., Limagne, E., Thibaudin, M., Truntzer, C., Bertaut, A., Rederstorff, E., & Ghiringhelli, F. (2020) · BMC Cancer · doi:10.1186/s12885-020-07253-x · Cited by 50
Opportunities and challenges in targeted therapy and immunotherapy for pancreatic cancer
Cao, D., Song, Q., Li, J., Jiang, Y., Wang, Z., & Lu, S. (2021) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2021.26 · Cited by 47
Which test for crossing survival curves? A user’s guideline
Dormuth, I., Liu, T., Xu, J., Yu, M., Pauly, M., & Ditzhaus, M. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01520-0 · Cited by 48
Prevalence of Germline Sequence Variations Among Patients With Pancreatic Cancer in China
Yin, L., Wei, J., Lu, Z., Huang, S., Gao, H., Chen, J., Guo, F., Tu, M., Xiao, B., Xi, C., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.48721 · Cited by 48
Binding Sites of Anticancer Drugs on Human Serum Albumin (HSA): A Review
Molaei, P., Mahaki, H., Manoochehri, H., & Tanzadehpanah, H. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666220426124834 · Cited by 47
A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
Xue, H., Bhardwaj, A., Yin, Y., Fijen, C., Ephstein, A., Zhang, L., Ding, X., Pascal, J. M., VanArsdale, T. L., & Rothenberg, E. (2022) · Science Advances · doi:10.1126/sciadv.abq0414 · Cited by 52
Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184351 · Cited by 52
Babiker, H. M., Picozzi, V. J., Chandana, S. R., Melichar, B., Kasi, A., Gang, J., Gallego, J., Bullock, A., Chunyi, H., Wyrwicz, L. S., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00746 · Cited by 56
Self-citationMaynard, H., Stadler, Z. K., Berger, M. F., Solit, D. B., Ly, M., Lowery, M. A., Mandelker, D. L., Zhang, L., Jordan, E., Dika, I. E., et al. (2020) · Cancer · doi:10.1002/cncr.32740 · Cited by 48
Self-citationFamilial Pancreatic Cancer: Current Perspectives
Llach, J., Carballal, S., & Moreira, L. (2020) · Cancer Management and Research · doi:10.2147/cmar.s172421 · Cited by 51
Recent advancements in PARP inhibitors-based targeted cancer therapy
Zhou, P., Wang, J. L., Mishail, D., & Wang, C. (2020) · Precision Clinical Medicine · doi:10.1093/pcmedi/pbaa030 · Cited by 50
Ricci, A. D., Rizzo, A., Novelli, M., Tavolari, S., Palloni, A., Tober, N., Abbati, F., Mollica, V., Lorenzo, S. D., Turchetti, D., et al. (2020) · Anticancer Research · doi:10.21873/anticanres.13989 · Cited by 47
Gorchs, L., & Kaipe, H. (2021) · Cancers · doi:10.3390/cancers13122995 · Cited by 56
Fennell, D. A., Porter, C., Lester, J. F., Danson, S. J., Blackhall, F. H., Nicolson, M. C., Nixon, L. S., Gardner, G. M., White, A., Griffiths, G. O., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101595 · Cited by 47
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Menezes, M. C. S., Raheem, F., Mina, L. A., Ernst, B. J., & Batalini, F. (2022) · Cancers · doi:10.3390/cancers14174332 · Cited by 48
Update on Emerging Therapies for Advanced Colorectal Cancer
Alese, O. B., Wu, C. S.-Y., Chapin, W. J., Ulanja, M. B., Zheng-Lin, B., Amankwah, M., & Eads, J. R. (2023) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_389574 · Cited by 50
Ji, W., Weng, X., Xu, D., Cai, S., Lou, H., & Ding, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.050 · Cited by 44
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
Joris, S., Denys, H. G., Collignon, J., Rasschaert, M. A., de Roodenbeke, D. T., Duhoux, F. P., Canon, J. L., Tejpar, S., Mebis, J., Decoster, L., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.102041 · Cited by 49
Next-generation therapies for pancreatic cancer
Buckley, C. W., & O'Reilly, E. M. (2024) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2024.2322648 · Cited by 49
Self-citationWitz, A., Dardare, J., Betz, M., Michel, C., Husson, M., Gilson, P., Merlin, J., & Harlé, A. (2025) · Biomarker Research · doi:10.1186/s40364-025-00740-y · Cited by 52
Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Kung, H., & Yu, J. (2023) · MedComm · doi:10.1002/mco2.216 · Cited by 44
Mandelker, D. L., Marra, A., Zheng-Lin, B., Selenica, P., Blanco-Heredia, J., Zhu, Y., Gazzo, A. M., Wong, D., Yelskaya, Z., Rai, V., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00561 · Cited by 45
Self-citationParsels, L. A., Engelke, C. G., Parsels, J. D., Flanagan, S. A., Zhang, Q., Tanska, D. M., Wahl, D. R., Canman, C. E., Lawrence, T. S., & Morgan, M. A. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0365 · Cited by 46
The State-of-the-Art of Phase II/III Clinical Trials for Targeted Pancreatic Cancer Therapies
García-Sampedro, A., Gaggia, G., Ney, A., Mahamed, I., & Acedo, P. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040566 · Cited by 47
SEOM clinical guidelines for pancreatic and biliary tract cancer (2020)
Gómez‐España, M. A., Montés, A. F., García‐Carbonero, R., Macarulla, T. M., Maurel, J., Martín, Á., Pazo-Cid, R., Vera, R., Carrato, A., & Feliú, J. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02573-1 · Cited by 45
Self-citationPARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
Csizmar, C. M., Saliba, A. N., Swisher, E. M., & Kaufmann, S. H. (2021) · Cancers · doi:10.3390/cancers13246385 · Cited by 45
Batalini, F., Gulhan, D., Mao, V. Y., Tran, A. V., Polak, M. M., Xiong, N., Tayob, N., Tung, N., Winer, E. P., Mayer, E. L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0749 · Cited by 50
Pancreas cancer and BRCA : A critical subset of patients with improving therapeutic outcomes
Momtaz, P., O’Connor, C. A., Chou, J. F., Capanu, M., Park, W., Bandlamudi, C., Berger, M. F., Kelsen, D. P., Suehnholz, S. P., Chakravarty, D., et al. (2021) · Cancer · doi:10.1002/cncr.33812 · Cited by 44
Self-citationTargeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer
Catalano, F., Borea, R., Puglisi, S., Boutros, A., Gandini, A., Cremante, M., Martelli, V., Sciallero, S., & Puccini, A. (2022) · Cancers · doi:10.3390/cancers14061388 · Cited by 44
The Role of the Microbiome in Pancreatic Cancer
Miyabayashi, K., Ijichi, H., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184479 · Cited by 48
The potential of PARP inhibitors in targeted cancer therapy and immunotherapy
Hunia, J., Gawalski, K., Szredzka, A., Suskiewicz, M. J., & Nowis, D. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1073797 · Cited by 45
Hammel, P. R., Kindler, H. L., Reni, M., Cutsem, E. V., Macarulla, T. M., Hall, C. M., Park, J. O., Hochhauser, D., Arnold, D., Oh, D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz406 · Cited by 44
Self-citationSmeby, J., Kryeziu, K., Berg, K. C. G., Eilertsen, I. A., Eide, P. W., Johannessen, B., Guren, M. G., Nesbakken, A., Bruun, J., Lothe, R. A., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.102923 · Cited by 45
The role of PARP inhibitors in BRCA mutated pancreatic cancer
Chi, J., Chung, S. Y., Parakrama, R. Y., Fayyaz, F., Jose, J., & Saif, M. W. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211014818 · Cited by 47
Pancreatic cancer intrinsic PI3Kα activity accelerates metastasis and rewires macrophage component
Thibault, B., Ramos‐Delgado, F., Tostivint, E. P., Therville, N., Cintas, C., Arcucci, S., Cassant‐Sourdy, S., Reyes‐Castellanos, G., Tosolini, M., Villard, A. V., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202013502 · Cited by 46
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Vanacker, H., Harter, P., Labidi‐Galy, S. I., Banerjee, S. N., Oaknin, A., Lorusso, D., & Ray-Coquard, I. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102255 · Cited by 46
Targeting DNA damage repair pathways in pancreas cancer
Crowley, F., Park, W., & O’Reilly, E. M. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09983-1 · Cited by 43
Self-citationCollet, L., Hanvic, B., Turinetto, M., Treilleux, I., Chopin, N., Saux, O. L., & Ray-Coquard, I. L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1354427 · Cited by 43
Mannucci, A., & Goel, A. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70035 · Cited by 54
Barayan, R., Ran, X., & Lok, B. H. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.89 · Cited by 43
T-Cell Immunity in Pancreatic Cancer
Ajina, R., & Weiner, L. M. (2020) · Pancreas · doi:10.1097/mpa.0000000000001621 · Cited by 46
Zuo, L., Tao, H., Xu, H., Li, C., Qiao, G., Guo, M., Cao, S., Liu, M., & Lin, X. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s265423 · Cited by 43
Yadav, S., Kasi, P. M., Bamlet, W. R., Ho, T. P., Polley, E. C., Hu, C., Hart, S. N., Rabe, K. G., Boddicker, N. J., Gnanaolivu, R. D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1788 · Cited by 44
The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer
Arai, H., Elliott, A., Xiu, J., Wang, J., Battaglin, F., Kawanishi, N. K., Soni, S., Zhang, W., Millstein, J., Sohal, D. P. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3635 · Cited by 46
Self-citationGupta, N., & Yelamanchi, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3158 · Cited by 47
Mas, L., Lupinacci, R. M., Cros, J. F., Bachet, J., Coulet, F., & Svrcek, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136756 · Cited by 43
Chu, Y., Yam, C., Yamaguchi, H., & Hung, M. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00870-7 · Cited by 47
Systemic immune-inflammation index: a prognostic tiebreaker among all in advanced pancreatic cancer.
Bittoni, A., Pecci, F., Mentrasti, G., Crocetti, S., Lupi, A., Lanese, A., Pellei, C., Ciotti, C., Cantini, L., Giampieri, R., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-3499 · Cited by 42
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42
Sokol, E. S., Jin, D. X., Fine, A. D., Trabucco, S. E., Maund, S. L., Frampton, G. M., Molinero, L. L., & Antonarakis, E. S. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00531 · Cited by 47
Valéry, M., Vasseur, D., Fachinetti, F., Boilève, A., Smolenschi, C., Tarabay, A., Antoun, L., Perret, A., Fuerea, A. C., Pudlarz, T., et al. (2023) · Cancers · doi:10.3390/cancers15184446 · Cited by 44
Precision medicine in pancreatic cancer: treating every patient as an exception
Herbst, B. T., & Zheng, L. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30175-x · Cited by 42
Luo, M., Zheng, F., Chen, W., Liang, Z.-M., Chandramouly, G., Tan, J., Willis, N. A., Chen, C.-H., Taveira, M. D. O., Zhou, X. Z., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-2739 · Cited by 40
Kim, E. J., Kim, Y. J., Lee, H. I., Jeong, S. H., Nam, H. J., & Cho, J. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134646 · Cited by 42
Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward
Franck, C., Müller, C., Rosania, R., Croner, R. S., Pech, M., & Venerito, M. (2020) · Cancers · doi:10.3390/cancers12071955 · Cited by 41
Ewing, A., Meynert, A. M., Churchman, M., Grimes, G. R., Hollis, R. L., Herrington, C. S., Rye, T., Bartos, C., Croy, I., Ferguson, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4068 · Cited by 40
Wang, Y., Zheng, K., Xiong, H., Huang, Y., Chen, X., Zhou, Y., Qin, W., Su, J., Chen, R., Qiu, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.762989 · Cited by 42
Aung, K. L., McWhirter, E., Welch, S. A., Wang, L. E., Lovell, S., Stayner, L.-A., Ali, S., Malpage, A., Makepeace, B., Ramachandran, M., et al. (2022) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-22-86 · Cited by 41
Malignant biliary obstruction due to metastatic non-hepato-pancreato-biliary cancer
Okamoto, T. (2022) · World Journal of Gastroenterology · doi:10.3748/wjg.v28.i10.985 · Cited by 42
Costanzo, F. D., Costanzo, F. D., Antonuzzo, L., Mazza, E., & Giommoni, E. (2023) · Cancers · doi:10.3390/cancers15020416 · Cited by 42
Cellular Responses to Widespread DNA Replication Stress
Nickoloff, J. A., Jaiswal, A. S., Sharma, N., Williamson, E. A., Tran, M. T., Arris, D., Yang, M., & Hromas, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316903 · Cited by 46
Ishiwatari, H., Ogura, T., Hijioka, S., Iwashita, T., Matsubara, S., Ishikawa, K., Niiya, F., Sato, J., Okuda, A., Ueno, S., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.02.012 · Cited by 41
Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Brozos-Vázquez, E., Toledano‐Fonseca, M., Costa‐Fraga, N., García‐Ortiz, M. V., Díaz‐Lagares, Á., Rodríguez‐Ariza, A., Aranda, E., & López‐López, R. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102719 · Cited by 50
E, E. R. P., Jonsson, P., Seier, K., Qin, L., Chi, P., Dickson, M. A., Gounder, M. M., Kelly, C. M., Keohan, M. L., Nacev, B. A., et al. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00122 · Cited by 41
Frank, K. J., Mulero-Sánchez, A., Berninger, A., Ruiz-Cañas, L., Bosma, A., Görgülü, K., Wu, N., Diakopoulos, K. N., Kaya-Aksoy, E., Ruess, D. A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100815 · Cited by 40
Self-citationChi, K. N., Castro, E., Attard, G., Smith, M. R., Sandhu, S. K., Efstathiou, E., Roubaud, G., Small, E. J., Gomes, A. P. D. S., Rathkopf, D. E., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.04.012 · Cited by 44
Cremin, C., Lee, M. K. C., Hong, Q., Hoeschen, C., Mackenzie, A., Dixon, K., McCullum, M., Nuk, J., Kalloger, S. E., Karasinska, J. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2973 · Cited by 41
Chittenden, A. B., Haraldsdóttir, S., Ukaegbu, C. I., Underhill-Blazey, M. L., Gaonkar, S., Uno, H., Brais, L. K., Perez, K. J., Wolpin, B. M., Syngal, S., et al. (2021) · JCO Oncology Practice · doi:10.1200/op.20.00678 · Cited by 42
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
Usón, P. L. S., Samadder, N. J., Riegert‐Johnson, D. L., Boardman, L., Borad, M. J., Ahn, D. H., Sonbol, M. B., Faigel, D. O., Fukami, N., Pannala, R., et al. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000414 · Cited by 41
Körfer, J., Lordick, F., & Hacker, U. T. (2021) · Cancers · doi:10.3390/cancers13205216 · Cited by 42
Kasuga, A., Okamoto, T., Udagawa, S., Mori, C., Mie, T., Furukawa, T., Yamada, Y., Takeda, T., Matsuyama, M., Sasaki, T., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031205 · Cited by 41
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Turpin, A., Neuzillet, C., Colle, E., Dusetti, N., Nicolle, R., Cros, J. F., de Mestier, L., Bachet, J., & Hammel, P. R. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221118019 · Cited by 41
Self-citationRecent advances in targeted therapy for pancreatic adenocarcinoma
Fang, Y., Yang, W., Niu, Y., & Sun, Y. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i4.571 · Cited by 40
Gaps and Opportunities in the Diagnosis and Treatment of Pancreatic Cancer
Caban, M., & Małecka-Wojciesko, E. (2023) · Cancers · doi:10.3390/cancers15235577 · Cited by 46
Watanabe, K., & Seki, N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020752 · Cited by 39
Gupta, M., Iyer, R. V., & Fountzilas, C. K. (2019) · Cancers · doi:10.3390/cancers11121980 · Cited by 40
Pancreatic Cancer Molecular Classifications: From Bulk Genomics to Single Cell Analysis
Pompella, L., Tirino, G., Pappalardo, A., Caterino, M., Ventriglia, A., Nacca, V., Orditura, M., Ciardiello, F., & Vita, F. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082814 · Cited by 40
Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
Singh, A. P., Shum, E., Rajdev, L. N., Cheng, H., Goel, S., Perez-Soler, R., & Halmos, B. (2020) · Cancers · doi:10.3390/cancers12051156 · Cited by 40
Thompson, E. D., Roberts, N. J., Wood, L. D., Eshleman, J. R., Goggins, M., Kern, S. E., Klein, A. P., & Hruban, R. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-0629-6 · Cited by 41
Missing the target in cancer therapy
Adashek, J. J., Goloubev, A., Kato, S., & Kurzrock, R. (2021) · Nature Cancer · doi:10.1038/s43018-021-00204-w · Cited by 40
Ma, Z., Sun, X., Zhao, Z., Lu, W., Guo, Q., Wang, S., You, J., Zhang, Y., & Liu, L. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.05.012 · Cited by 39
Cai, Z., Liu, C., Chang, C., Shen, C., Yin, Y., Yin, X., Jiang, Z., Zhao, Z., Mu, M., Cao, D., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105808 · Cited by 39
Ghanem, I., Lora, D., Herradón, N., de Velasco, G., Carretero-González, A., Varas, M. Á. J., de Parga, P. V., & Feliú, J. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100485 · Cited by 39
Hereditary breast and ovarian cancer: from genes to molecular targeted therapies
Ponti, G., Angelis, C. D., Ponti, R., Pongetti, L., Losi, L., Sticchi, A., Tomasi, A., & Özben, T. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2234488 · Cited by 42
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial
Knox, J. J., Jang, G. H., Grant, R. C., Zhang, A. X. W., Ma, L. X., Elimova, E. C., Jang, R., Moore, M. J., Biagi, J. J., Tehfe, M. A., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-60808-z · Cited by 39
Dullens, B., Putter, R. D., Lambertini, M., Toss, A., Han, S., Nieuwenhuysen, E. V., Gorp, T. V., Vanderstichele, A., Ongeval, C. V., Keupers, M., et al. (2020) · Journal of Oncology · doi:10.1155/2020/9873954 · Cited by 38
Homologous recombination repair deficiency as a therapeutic target in sarcoma
Oza, J. H., Doshi, S. D., Hao, L. Y., Musi, E., Schwartz, G. K., & Ingham, M. A. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.10.002 · Cited by 39
Elsayed, M., & Abdelrahim, M. (2021) · Biomedicines · doi:10.3390/biomedicines9040389 · Cited by 37
Dalmasso, B., Pastorino, L., Nathan, V., Shah, N. N., Palmer, J. M., Howlie, M., Johansson, P. A., Freedman, N. D., Carter, B. D., Beane-Freeman, L., et al. (2021) · Genetics in Medicine · doi:10.1038/s41436-021-01240-8 · Cited by 38
Genomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Gutiérrez, M. L., Muñoz‐Bellvís, L., & Órfão, A. (2021) · Cancers · doi:10.3390/cancers13174451 · Cited by 41
Walker, E. J., Goldberg, D., Gordon, K. M., Pedley, C., Carnevale, J. C., Cinar, P., Collisson, E. A., Tempero, M. A., Ko, A. H., Blanco, A. M., et al. (2021) · The Oncologist · doi:10.1002/onco.13968 · Cited by 40
Mainstreaming germline genetic testing for patients with pancreatic cancer increases uptake
Ramsey, M. L., Tomlinson, J., Pearlman, R., Abushahin, L. I., Aeilts, A. M., Chen, H.-Z., Chen, Y., Compton, A., Elkhatib, R. T., Geiger, L., et al. (2022) · Familial Cancer · doi:10.1007/s10689-022-00300-5 · Cited by 38
Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target
Gillson, J., El-Aziz, Y. S. A., Leck, L. Y. W., Jansson, P. J., Pavlakis, N., Samra, J. S., Mittal, A., & Sahni, S. (2022) · Cancers · doi:10.3390/cancers14143528 · Cited by 38
Evolving pancreatic cancer treatment: From diagnosis to healthcare management
Milella, M., Bassi, C., Boggi, U., Brunetti, O., Cavaliere, A., Crippa, S., Vita, F. D., Falconi, M., Frassineti, G. L., Giommoni, E., et al. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103571 · Cited by 37
Self-citationIncreasing Stress to Induce Apoptosis in Pancreatic Cancer via the Unfolded Protein Response (UPR)
Botrus, G., Miller, R. M., Usón, P. L. S., Kannan, G. S., Han, H., & Hoff, D. D. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010577 · Cited by 37
Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine
Li, B., Zhang, Q., Castaneda, C. N., & Cook, S. M. (2024) · Biomedicines · doi:10.3390/biomedicines12102175 · Cited by 38
PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Ricci, A. D., Rizzo, A., Bonucci, C., Tober, N., Palloni, A., Mollica, V., Maggio, I., Deserti, M., Tavolari, S., & Brandi, G. (2020) · Medicines · doi:10.3390/medicines7090054 · Cited by 37
Li, T., Ren, T., Huang, C., Li, Y., Yang, P., Che, G., Luo, L., Chen, Y., Peng, S., Lin, Y., et al. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114396 · Cited by 37
Metadata
- Authors
- Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., Reinacher-Schick, A., Tortora, G., Algül, H., O’Reilly, E. M., McGuinness, D., Cui, K. Y., Schlienger, K., Locker, G. Y., & Kindler, H. L.
- Affiliations
- Tel Aviv University (IL)
- From the Oncology Institute, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel (T.G.); Hôpital Beaujon (Assistance Publique–Hôpitaux de Paris), Clichy, and University Paris VII, Paris (P.H.); IRCCS Ospedale San Raffaele Scientific Institute, Milan (M.R.), Azienda Ospedaliera Universitaria Integrata Verona, Verona (G.T.), and Fondazione Policlinico Universitario Gemelli IRCCS, Rome (G.T.) — all in Italy; University Hospitals Gasthuisberg and KU Leuven, Leuven, Belgium (E.V.C.); Vall...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-25
- Volume
- 381
- Issue
- 4
- Pages
- 317-327
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC6810605
- OpenAlex
- W2947826965
- Cited by
- 2,302
- References
- 24
- Citations by year
- 2026: 195 · 2025: 268 · 2024: 292 · 2023: 312 · 2022: 412 · 2021: 452 · 2020: 299 · 2019: 66
- FWCI
- 129.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lirias (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- AstraZeneca (NA)
- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc (NA)
- NIH/NCI Cancer Center Support Grant (P30-17 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Keywords
- olaparib, PARP inhibitors, germline BRCA mutation, metastatic pancreatic cancer, maintenance therapy, progression-free survival, overall survival, quality of life, adverse events, platinum-based chemotherapy, PARP inhibitor resistance, DNA repair deficiency, targeted therapy, interim analysis, predictive biomarkers, treatment discontinuation, health-related quality of life
- MeSH terms
- Progression-Free Survival, Adenocarcinoma, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Double-Blind Method, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pancreatic Neoplasms, Phthalazines, Piperazines, Germ-Line Mutation, Genes, BRCA1, Genes, BRCA2, Kaplan-Meier Estimate, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
